Scholarlink

Background <p>Hypoxia is a common complication in hysteroscopic surgery under sedation with conventional opioids. Oliceridine, a novel G protein-biased μ-opioid receptor agonist, provides effective analgesia with fewer opioid-related adverse events, but its impact on intraoperative hypoxia in hysteroscopy remains unclear.</p> Methods <p>This is a single-center, prospective, double-blind, randomized clinical trial (TRN: ChiCTR2400090351), patients scheduled for hysteroscopic surgery under sedation were enrolled. Participants were randomized (1:1) to receive sufentanil (0.15 μg·kg⁻¹) or oliceridine (40 μg·kg⁻¹), combined with propofol (1.5 mg·kg⁻¹). The primary outcome was the incidence of intraoperative hypoxia from sedative drug initiation to hysteroscopy completion. Secondary outcomes included subclinical respiratory depression, severe hypoxia, airway interventions, supplemental propofol requirements, pain scores, arterial blood gas analysis, and patient and surgeon satisfaction.</p> Results <p>Among 492 randomized patients, 482 (98%) completed the trial. The incidence of intraoperative hypoxia is significantly lower in the oliceridine group (24 [9.8%] of 246 patients) than that in the sufentanil group (48 [19.5%] of 246 patients; RR, 0.50 [95% CI, 0.32–0.79]; <i>P</i> = 0.002). The lowest oxygen saturation is higher in the oliceridine group (99.0 [94.0, 100.0] vs 97.0 [90.0, 100.0], <i>P</i> &lt; 0.001). Compared to sufentanil group, oliceridine group requires less propofol intraoperatively (median difference: 10.0 mg, 95% CI: 0.0 to 14.5; <i>P</i> = 0.03), has lower PaCO<sub>2</sub> in Post-Anesthesia Care Unit (median difference: 1.0 mmHg, 95% CI: 0.0 to 2.0; <i>P</i> = 0.02) and a reduced base excess (mean difference: 0.34 mmol/L, 95% CI: 0.03 to 0.66; <i>P</i> = 0.03). In addition, both patient satisfaction and surgeon satisfaction are significantly higher (<i>P</i> = 0.003 and <i>P</i> = 0.002) in oliceridine group.</p> Conclusions <p>Oliceridine reduces the incidence of intraoperative hypoxia during hysteroscopic surgery under sedation, suggesting it may be a safer alternative to sufentanil.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of oliceridine on hypoxia during sedated hysteroscopy: a Phase 4 randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Ye Liu,
  • Mingshu Tao,
  • Biran Dai,
  • Xia Yin,
  • Xinyu Gu,
  • Jie Xiao,
  • Jun-Li Cao,
  • Weifeng Yu,
  • Liqun Yang,
  • Song Zhang

摘要

Background

Hypoxia is a common complication in hysteroscopic surgery under sedation with conventional opioids. Oliceridine, a novel G protein-biased μ-opioid receptor agonist, provides effective analgesia with fewer opioid-related adverse events, but its impact on intraoperative hypoxia in hysteroscopy remains unclear.

Methods

This is a single-center, prospective, double-blind, randomized clinical trial (TRN: ChiCTR2400090351), patients scheduled for hysteroscopic surgery under sedation were enrolled. Participants were randomized (1:1) to receive sufentanil (0.15 μg·kg⁻¹) or oliceridine (40 μg·kg⁻¹), combined with propofol (1.5 mg·kg⁻¹). The primary outcome was the incidence of intraoperative hypoxia from sedative drug initiation to hysteroscopy completion. Secondary outcomes included subclinical respiratory depression, severe hypoxia, airway interventions, supplemental propofol requirements, pain scores, arterial blood gas analysis, and patient and surgeon satisfaction.

Results

Among 492 randomized patients, 482 (98%) completed the trial. The incidence of intraoperative hypoxia is significantly lower in the oliceridine group (24 [9.8%] of 246 patients) than that in the sufentanil group (48 [19.5%] of 246 patients; RR, 0.50 [95% CI, 0.32–0.79]; P = 0.002). The lowest oxygen saturation is higher in the oliceridine group (99.0 [94.0, 100.0] vs 97.0 [90.0, 100.0], P < 0.001). Compared to sufentanil group, oliceridine group requires less propofol intraoperatively (median difference: 10.0 mg, 95% CI: 0.0 to 14.5; P = 0.03), has lower PaCO2 in Post-Anesthesia Care Unit (median difference: 1.0 mmHg, 95% CI: 0.0 to 2.0; P = 0.02) and a reduced base excess (mean difference: 0.34 mmol/L, 95% CI: 0.03 to 0.66; P = 0.03). In addition, both patient satisfaction and surgeon satisfaction are significantly higher (P = 0.003 and P = 0.002) in oliceridine group.

Conclusions

Oliceridine reduces the incidence of intraoperative hypoxia during hysteroscopic surgery under sedation, suggesting it may be a safer alternative to sufentanil.